Add BrightSurf on Google Email

Journal of the National Cancer Institute


Studies show that CYP2D6 genotype does not predict tamoxifen benefit

Two studies found that CYP2D6 genotypes associated with reduced enzyme activity do not predict clinical responsiveness to adjuvant tamoxifen therapy among postmenopausal women. This challenges the conventional hypothesis that poor metabolizers experience fewer side effects and may receive less benefit from tamoxifen.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 6, 2012

The challenges of cancer vaccines

Therapeutic cancer vaccines are being evaluated in clinical trials with immune checkpoint inhibitors and small-molecule targeted therapies to overcome immunosuppressive entities. Patients with fewer chemotherapeutic regimens respond better to vaccines, indicating a shift towards combination therapies.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 6, 2012

Studies show exposure to diesel exhaust may increase lung cancer mortality

A cohort study and nested case-control study found a statistically significantly increased risk of lung cancer with increasing diesel exhaust exposure among workers and urban populations. Studies suggest stringent occupational and environmental standards are necessary to reduce the health burden of carcinogenic diesel exhaust.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 2, 2012

Studies on smoking cessation in ethnic minorities

A study published in the Journal of the National Cancer Institute found that telephone counseling services doubled the odds of quitting smoking among Chinese-, Korean-, and Vietnamese-speaking smokers. In contrast, a second study on bupropion SR showed promise for African American light smokers during medication phase but lacked long-t...

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 25, 2012

Younger breast cancer patients have more adverse quality-of-life issues

A study published in the Journal of the National Cancer Institute found that younger women with breast cancer experience decreased health-related quality of life, including increased psychological distress, weight gain, and early onset menopause. Personalized treatment approaches are crucial to mitigate these side effects.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 20, 2012

Study showed oxaliplatin improved colon cancer patient survival

A recent study found that adding oxaliplatin to adjuvant chemotherapy for stage III colon cancer patients in the general population improved overall survival rates. The research also showed that this combination therapy was effective across various practice settings, including older and minority patients with comorbid conditions.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 20, 2012

Autologous stem cell transplantation does not improve os in patients with follicular lymphoma

A systematic review and meta-analysis of randomized control trials found no improvement in overall survival for adult patients with advanced follicular lymphoma who received high-dose chemotherapy and ASCT compared to conventional-dose chemotherapy alone. The study concluded that HDC-ASCT is not effective as a primary treatment option.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateDec 21, 2011

Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy

A study found APBIb use increased from 0.4% to 6.6% between 2000 and 2007, with wide regional disparities and racial/ethnic differences in utilization. The authors suggest unwarranted variation in practice may be present, highlighting the need for further research on APBI effectiveness.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateDec 16, 2011

Fecal occult blood testing effective in colonoscopy screenings

A study published in the Journal of the National Cancer Institute found that fecal immunochemical testing (FIT) is more effective than guaiac fecal occult blood testing (gFOBT) in colonoscopy screenings, increasing attendance and diagnostic yield while reducing false positives. FIT is also cost-effective and clinically beneficial for d...

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateNov 9, 2011

Concurrent chemo and radiation confers survival benefit in nasopharyngeal carcinoma patients

A phase III trial found that concurrent chemo-radiotherapy significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma. The treatment regimen resulted in higher progression-free and distant metastasis-free survival rates compared to radiation alone.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateNov 4, 2011

European studies on risks of hepatocellular carcinoma

Research from the European Prospective Investigation into Cancer and Nutrition (EPIC) study found that 47.6% of hepatocellular carcinoma cases were associated with smoking, while chronic hepatitis B and C infection was the strongest risk factor. The study also highlights the importance of quitting smoking to reduce liver cancer risk.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateOct 21, 2011

Survival disparities in African-American and white colo-rectal cancer patients

A study published in the Journal of the National Cancer Institute found that African-American patients with resected stage II and III colon cancer experienced poorer overall and recurrence-free survival compared to whites. The five-year relative survival rates for black and white colorectal cancer patients were 57% and 68%, respectively.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateOct 12, 2011

Company stock prices before public announcements of oncology trial results

Research found that drug company stock prices increased by 13.7% before positive phase III clinical trials and decreased by 0.7% before negative trials. The study also showed that stock prices of established companies with positive trial results were more likely to increase than those of smaller companies with negative trial results.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateSep 26, 2011

Children and adolescent mobile phone users at no greater risk of brain cancer than non-users

A recent study published in the Journal of the National Cancer Institute found that children and adolescent mobile phone users are not at a statistically significant increased risk of brain cancer compared to non-users. The study included data from over 352 brain cancer patients and 646 control subjects, and found no clear exposure-res...

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJul 27, 2011

DNA repair system affects colon cancer recurrence and survival

Patients with mismatch repair defects have lower tumor recurrence rates, longer remissions, and improved overall and disease-free survival compared to those without the defects. The study suggests that these defects are associated with a reduced response to 5-FU therapy, particularly in patients with inherited defects.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMay 19, 2011

Breast cancers found between mammograms more likely to be aggressive

A study published in the Journal of the National Cancer Institute found that breast cancers discovered between screening mammograms tend to be more aggressive and have a poorer prognosis. The research compared data from women with interval cancers (detected between mammograms) to those detected during routine screening.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMay 3, 2011

Use of costly breast cancer therapy strongly influenced by reimbursement policy

A study found that Medicare reimbursement policy significantly affects the use of costly breast cancer therapy, including intensity-modulated radiation therapy (IMRT). The analysis showed a sharp increase in IMRT usage and costs between 2001 and 2005, with billing rates varying by region and treatment setting.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateApr 28, 2011

Tumors resistant to radiation therapy may be controlled by the MET oncogene

Researchers discovered that ionizing radiation drives overexpression and activity of MET through the ATM and NF-κB signaling pathways, making some tumor cells resistant to radiation. Inhibiting MET counteracted this increased invasiveness, promoting apoptosis in tumor cells and enhancing the effect of radiation.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateApr 4, 2011

FDA considers new rules to speed up confirmatory trials of drugs granted accelerated approval

The FDA is considering new rules to speed up confirmatory trials of drugs granted accelerated approval, following a review that found six indications remained on the market without confirmation. The median time between accelerated and regular approval was 3.9 years, with some drugs remaining on the market for over 10 years.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 25, 2011

Lung cancer study finds mentholated cigarettes no more harmful than regular cigarettes

A large prospective study of black and white smokers found that mentholated cigarettes are associated with a lower lung cancer incidence and fewer lung cancer deaths than regular cigarettes. The researchers also found that menthol smokers reported smoking fewer cigarettes per day, but had similar quit rates as non-menthol smokers.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 23, 2011